Clinical Trial

PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This multicenter, randomized, double-blind phase III study intends to recruit about 878 patients, including PD-L1 positive 660 patients, who have received radical gastrectomy (R0 resection, D2 or more extended lymphadenectomy) with postoperative pathological stage IIB or III (AJCC Cancer Staging Manual, 8th Edition) gastric or EGJ adenocarcinoma to evaluate the efficacy and safety of JS001 combined with postoperative adjuvant chemotherapy versus placebo combined with postoperative adjuvant chemotherapy.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-01-04; most recent amendment 2026-07-03.
Status change: Recruiting → Active, Not Recruiting 2025-01-13
Status change: Not Yet Recruiting → Recruiting 2022-04-01
Trial Details
NCT Number NCT05180734
Lead Sponsor Shanghai Junshi Bioscience Co., Ltd.
Conditions Gastric or Esophagogastric Junction Adenocarcinoma
Enrollment 878 participants
Start Date 2022-02-10
Primary Completion 2027-03-31 (estimated)
Study Completion 2028-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-07